

Controlled Monofunctionalization of Molecular Spherical Nucleic Acids on a Buckminster Fullerene Core

Vijay Gulumkar,[‡] Antti Äärelä,[‡] Olli Moisio, Jani Rahkila, Ville Tähtinen, Laura Leimu, Niko Korsoff, Heidi Korhonen, Päivi Pöijärvi-Virta, Satu Mikkola, Victor Nesati, Elina Vuorimaa-Laukkanen, Tapani Viitala, Marjo Yliperttula, Anne Roivainen, and Pasi Virta*

Cite This: *Bioconjugate Chem.* 2021, 32, 1130–1138

Read Online


ACCESS |

Metrics & More

Article Recommendations

Supporting Information

ABSTRACT: An azide-functionalized 12-armed Buckminster fullerene has been monosubstituted in organic media with a substoichiometric amount of cyclooctyne-modified oligonucleotides. Exposing the intermediate products then to the same reaction (i.e., strain-promoted alkyne–azide cycloaddition, SPAAC) with an excess of slightly different oligonucleotide constituents in an aqueous medium yields molecularly defined monofunctionalized spherical nucleic acids (SNAs). This procedure offers a controlled synthesis scheme in which one oligonucleotide arm can be functionalized with labels or other conjugate groups (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, DOTA, and Alexa-488 demonstrated), whereas the rest of the 11 arms can be left unmodified or modified by other conjugate groups in order to decorate the SNAs' outer sphere. Extra attention has been paid to the homogeneity and authenticity of the C₆₀-azide scaffold used for the assembly of full-armed SNAs.



INTRODUCTION

Spherical nucleic acids (SNAs, introduced originally by the Chad Mirkin laboratory) consist of an appropriate core (gold, silica, liposomes, proteins) and densely packed oligonucleotide (ON) chains.^{1–7} They share many beneficial properties that overcome some of the major shortcomings perceived for therapeutic ONs: they have efficient free cellular uptake via class A scavenger receptor-mediated endocytosis (which correlates with the density and chemistry of the component ONs),^{8,9} they have muted innate immune responses and resistance to nuclease degradation (due to steric reasons), and they are large enough to avoid renal clearance. The cellular uptake occurs via an endosomal pathway,^{8–10} and SNAs are able to silence target RNAs via steric blocking, once they enter into the cytoplasm.¹¹ Also, small interfering RNAs (siRNAs) can work in spherical formulation. Dicer is able to cleave siRNAs from SNAs and release them for the canonical RNA interference pathway.¹² Most of the reported SNAs are polydisperse structures. The polydispersity may be a shortcoming as the data shows a similar behavior, but still a population of particles lacking thorough characterization of the molecules exists, something that is readily accessible for covalent ON conjugates. Recently, a molecular SNA, based on a Buckminster C₆₀-fullerene core, has been described.¹³ This structure, consisting of antisense ON sequences on the C₆₀ core, was dense enough to induce scavenger receptor-mediated endocytosis. The internalization of these particles to breast cancer (MCF7) cells was determined to be ca. 500-fold compared to the free component ONs. Regulation of protein


expression by an antisense ON that targeted human epidermal growth factor receptor 2 (HER2) mRNA transcripts was also demonstrated.


Our interest in molecularly defined SNAs is to apply them as delivery vehicles together with the covalent conjugation strategy. The rationale of this idea is that radial formulation could be a simple option to emphasize the ligand-specific effect on the outer sphere of the SNAs and at the same time hide the unfavorable distribution properties of negatively charged ONs.^{14–17} For the monitoring of cellular uptake and biodistribution of these decorated SNAs, appropriate labeling is needed, which may cause a misleading distribution and cellular delivery of the actual structure (if all arms are labeled). Therefore, to keep the label effect minimal, an established method that allows controlled monofunctionalization of the SNAs is valuable. Furthermore, the controlled monofunctionalization can be utilized to integrate SNAs specifically with other delivery vehicles. In the present study, an azide-functionalized 12-armed Buckminster fullerene (1) is exposed to a substoichiometric amount of cyclooctyne-modified and -labeled (DOTA and Alexa 488) ONs, which gave the monofunctionalized fullerene in relatively high yields. The

Received: April 13, 2021

Revised: May 7, 2021

Published: May 16, 2021



Scheme 1. ^1H NMR (500 MHz, CDCl_3) Spectrum of **1** (A) and **2** (B)^a

^aConditions: (i) bis(2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)malonate, CBr_4 , 1,8-diazabicyclo[5,4,0]undec-7-ene (DBU), *o*-dichlorobenzene under argon, 3 days at room temperature.

isolated intermediate products were then exposed to an excess of slightly different ON constituents in an aqueous medium, which gave the monolabeled full-armed SNAs. This two-step process was noticed to be crucial, not only for the controlled assembly but also for the preparation of the C_{60} -based SNAs in more general, as the solubility properties of the lipophilic C_{60} core and hydrophilic ONs severely retard the full decoration in one reaction medium only. Reverse-phase high-performance liquid chromatography (RP-HPLC), native polyacrylamide gel electrophoresis (PAGE), capillary electrophoresis (CE), MS spectroscopy, dynamic light scattering (DLS), and size exclusion chromatography equipped with a multiple-angle light-scattering detector (SEC-MALS) were used to analyze the end products. We also paid extra attention to the homogeneity and authenticity of the initial C_{60} -azide scaffold (**1**) as it is readily contaminated by a hardly distinguishable azide- C_{60} [3 + 2] cycloaddition side product that would hamper the assembly, purification, and identification of the target SNAs. Overall, this procedure allows a controlled synthesis scheme in which one of the ON arms of SNAs can be selectively functionalized with labels or other conjugate groups. In one case, *D*-galactose-conjugated ONs were used to decorate the outer sphere. In addition, radiolabeling of a DOTA-labeled SNA has been demonstrated.


RESULTS AND DISCUSSION

Synthesis and Purification of the C_{60} -Azide Core (**1**).

The C_{60} -azide scaffold (**1**) was synthesized following a previously published procedure (Scheme 1).¹³ However, in our hands, Bingel's cyclopropanation^{18,19} between Buckminster fullerene (C_{60}) and bis(2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)malonate gave a mixture of compounds (**1** and **2**, ca. 1:1, n/n) with equal molecular masses and similar NMR data (**2** with markedly broader resonances, A vs B in Scheme 1). Repeated column chromatography and RP-HPLC purification were needed to obtain the homogenized **1** in

15% overall isolated yield, which was used for the preparation of SNAs. In order to provide further understanding of the products' identity and applicability for the SNAs' assembly, preliminary SPAAC trials were carried out: Both **1** and **2** were exposed to an excess of bicyclo[6.1.0]non-4-yn-9-ylmethanol- and 5'-2-(bicyclo[6.1.0]non-4-yn-9-yl)ethylphosphate (BCN)-modified T_6 sequence (ON1, following the two-step process in Scheme 2). MS (ESI-TOF) analysis verified that all 12 arms of **1** could be readily functionalized, but reactions with **2** stacked to undecafunctionalized products (Figures S6 and S7). ^1H - ^{15}N heteronuclear multiple bond correlation (HMBC) analysis was used to further verify the authenticity of **2**, which revealed that part of the nitrogen signals was characteristic to triazol and not entirely to alkylazide (Figures S8 and S9). The fact that the [3 + 2] cycloaddition occurred upon Bingel's cyclopropanation is understandable, as this reaction has been used to functionalize the C_{60} core in very similar conditions.^{20–24} For further evidence, ad hoc-synthesized triazolino fullerenes were synthesized by treating C_{60} with 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethanol. The NMR signals of the triazolino fullerenes (di-, tri-, and tetrafunctionalized products obtained, Scheme S1) were comparable to trace signals of **2**.

Synthesis of Oligonucleotides. For the assembly of SNAs (S1–S6), BCN-modified ONs (ON1–ON3, ON5, and ON7–ON10, Scheme 2) were synthesized using an automated DNA/RNA synthesizer. A standard phosphoramidite coupling cycle and commercially available 2'-*O*-methylribonucleotide and 2'-deoxyribonucleotide building blocks were used for the assembly. 3-Phenyl 1,2,4-dithiazoline-5-one (POS) was used as a sulfurization reagent for the synthesis of ON5. Our previously reported customized solid supports^{25,26} were utilized for the synthesis of appropriately 3'-modified ONs: ON7 and ON10 with a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and a *D*-galactose moiety, respectively. While ON1 and ON2 are short sequences,

Scheme 2^a

^aConditions: (i) BCN-modified oligonucleotide **1** (5 equiv) in DMSO, overnight at 25 °C, (ii) AF-488 NHS ester, 0.1 M sodium borate (pH 8.5), overnight at 25 °C, (iii) **C1–C7**, BCN-modified oligonucleotide (1.2 equiv/arm) in aqueous 1.5 M NaCl, 3 days at 25 °C.

preliminarily used to demonstrate the SNA's assembly (**S1** and **S2**), **ON3–ON10** are biologically active sequences. **ON3** (and **ON4**) is an antisense sequence that targets HER2 mRNA transcripts. Its biological activity in SNA formulation has previously been demonstrated.¹³ The phosphorothioate (PS) sequence of **ON5** (and **ON6**) is a splice switching ON that prevents expression of an androgenic receptor variant (AR-V7) in prostate cancer cells.²⁷ The 2'-O-methylated sequence found in **ON7**, **ON9**, and **ON10** is complementary to micro-RNA 15b that is involved in hepatocyte apoptosis.^{28,29} We have previously ⁶⁸Ga labeled this same ON and its glycoconjugates and studied their biodistribution by in vivo positron emission tomography/computed tomography (PET/CT) imaging.^{30–32}

Controlled Assembly of Monofunctionalized SNAs on the C₆₀-Azide Core. In initial trials, the C₆₀-azide core **1** was dissolved in a minimum volume of DMSO and treated with an excess (>12 equiv) of BCN-modified oligonucleotides in an

aqueous solution containing 1.5 M NaCl.¹³ However, the drastically different solubility properties between the lipophilic C₆₀-azide core (**1**) and the hydrophilic ONs retarded the SPAAC conjugation, and complex mixtures of products were obtained (reactions using different DMSO–H₂O ratios, different spacers between the ONs and the core, BCN- vs dibenzocyclooctyne-modified ONs, and different temperature were attempted). This guided us to try a two-step process in which **1** was first conjugated with ONs in DMSO, and once the partially functionalized more hydrophilic intermediate products were obtained, the reaction was changed to an aqueous medium to yield full-armed SNAs. Interestingly, monofunctionalization proceeded in DMSO (Figure 1A, Scheme S2) with a reasonable excess of **1**, which could be utilized for the controlled assembly of heteroantennary SNAs (**S1–S6**, Scheme 2). In optimized conditions (Scheme 2), BCN-modified ONs (**ON1–3**, **ON5**, and **ON7**) were treated with 5 equiv of **1** in DMSO to yield monofunctionalized C₆₀–




Figure 1. (A and C) Examples of RP-HPLC profiles of crude product (C7 and S5) mixtures. (B) Example of the MS-ESI spectrum of purified monosubstituted C₆₀-ON-conjugate (C7). (D) Example of the RP-HPLC profile of purified SNA (S5).




Figure 2. (A) Example of capillary electrophoregrams (CE) of purified SNA (S5). (B) Polyacrylamide gel electrophoregrams (PAGE) of purified SNAs (S1–S6). (C) Example of the SEC-MALS profile of purified SNA (S5) used to evaluate the molecular mass. For the conditions, see Experimental Section.

ON conjugates (C1–C3, C5, and C7) in relatively high RP-HPLC-isolated yields (45–50%). The remaining excess of **1** could be reisolated (cf. Figure 1A) and reused. The amino-modified conjugates (C3 and C5) were labeled with Alexa-488-*N*-hydroxysuccinimide (NHS) ester, and the conjugates (C1, C2, C4, C6, and C7) were then dissolved in aqueous 1.5 M NaCl solution and mixed with a slight excess (12 equiv) of BCN-ONs (ON1, ON5, and ON8–ON10).^{33–35} After incubation for 2 days at room temperature, one additional equivalent of BCN-ONs was added to confirm the completion of the full decoration (in overall 1.2 equiv/arm). The reaction mixtures were then incubated one more day (3 days total) and subjected as such to RP-HPLC (Figure 1C, Scheme S2). The obtained SNAs (S1–S6) were isolated in 40–57% yield according to UV absorbance at 260 nm (S1, S2, S5, and S6) and 488 nm (S3 and S4).

Characterization of the SNAs. The homogeneity and identity of the RP-HPLC-isolated SNAs were evaluated by PAGE, CE, SEC-MALS, and MS-ESI spectroscopy. As seen on

PAGE (Figure 2B), each SNA resulted in a distinct and relatively sharp band. The stereoisomeric phosphorothioate backbone of S4 caused a blurred band compared to other SNAs. On the electrophoregrams of larger SNAs (S5 and S6), faster eluting trace products (<5% of the total intensity) could be additionally observed that indicated incomplete decoration. Fractionation by RP-HPLC (Figure 1C) did not affect the results on PAGE, neither did the prolonged reaction time nor a higher excess of BCN-ONs (ON9 and ON10) used for the SPAAC conjugation. Despite these traces of side products (most likely 11-armed SNAs), the overall purity of the assembled SNAs after single RP-HPLC purification proved relatively high on PAGE. Next, the applicability of CE to evaluate the homogeneity of the SNAs was demonstrated (Figure 2A and Scheme S2). CE could not discriminate traces of incomplete (11-armed) products from the full-armed SNAs, but it proved to be a valuable tool to confirm the absence of smaller component ONs. SEC-MALS is a common technique employed to estimate the homogeneity, aggregation tendency,

and molecular weight of biomolecules.³⁶ This is particularly useful for large molecular weight compounds (>100 kDa), characterization of which is often hardly accessible by MS spectroscopy. This was the case also with SNAs. Acceptable m/z data (a spectrometer equipped with a hybrid quadrupole orbitrap and nano ESI ionization was used) could be obtained for small model SNAs **S1** and **S2** (Figure S12), whereas humps of overlapping multiply charged ion patterns, unsuitable for reliable MS characterization, were obtained for **S3–S6**. In fact, even **S1** and **S2** were prone to form stable multiple sodium adducts (Figure S12), and the observed molecular masses were 0.1 and 0.2 kDa higher compared to the calculated values (Table 1, entries 1 and 2). Therefore, we applied SEC-MALS

Table 1. Molecular Masses of SNAs S1–S6

SNA	calculated molecular mass (kDa)	observed molecular mass (kDa)	hydrodynamic size (nm)
S1	27.6	27.8 ^a	9.2 ± 1.2
S2	27.6	27.7 ^a	9.6 ± 2.5
S3	61.2	62.6 ± 0.4 ^b	11.8 ± 0.6
S4	107.3	106.8 ± 3.6 ^b	16.2 ± 0.1
S5	109.9	109.3 ± 2.1 ^b	19.0 ± 2.0
S6	113.2	107.4 ± 2.3 ^b	21.4 ± 0.8

^aA hybrid quadrupole-orbitrap spectrometer with nano ESI-ionization was used for mass analysis (cf. Figure S12). ^bThe values were obtained by SEC-MALS-based estimation of the molecular mass (cf. Figure 2C).

to estimate the molecular weights of **S3–S5**. The samples of **S3–S5** were eluted with 150 mM phosphate buffer (pH 7) through a 300 Å, 2.7 μm, 4.6 × 300 mm SEC column. As seen in Figure 2C and Figure S12, each SNA resulted in a major peak (retention time ca. 7 min) that represented the 70–80% mass fraction of the sample. The MALS-based estimation of the molecular weights extracted from the major peaks matched relatively well with the expected calculated values (Table 1, entries 3–6). It may be worth mentioning that the errors of the observed molecular masses were less than the molecular mass of the component ONs. In each case, faster eluting fractions (retention time ca. 5.0–6.5 min) were observed also, the

molecular weight of which (>200 kDa) may be attributed to aggregation of the SNAs (Figure 2C and Figure S12). Together with the molecular masses obtained for small model SNAs **S1** and **S2** and the SEC-MALS-based characterization of SNAs **S3–S6**, the authenticity of the products could be verified. Finally, the hydrodynamic diameter of the SNAs was determined by DLS. The diameters (ranging from 9.2 to 21.4 nm, Table 1) of **S1–S6** correlated with the lengths of the component ONs.

Melting Analysis (T_m) and Titration of SNA with a Complementary RNA Strand. In order to evaluate the hybridization properties of the C₆₀-based SNAs, UV-melting profile experiments (T_m) and titration of **S4** with a short model sequence of AR-V7 pre-mRNA were carried out. The **S4**–RNA duplex resulted in a –3 °C decrease in the T_m value when compared to the corresponding free duplex (Figure 3A). Furthermore, gentler melting profiles were observed, which was more obvious, when fully hybridized **S4** was compared to a partially hybridized one (12 vs 6 equiv of complementary strands). This indicates electrostatic repulsion/steric crowding between the duplexes on fully loaded SNA (**S4** + 12 equiv of RNA). This observation is consistent with the previous findings in which a retarded loading of siRNAs onto SNAs has been observed.^{12,37–39} However, it is notable that the fully loaded SNA (**S4** + 12 equiv of RNA) was virtually stable below the physiological temperature and the observed “premature” partial denaturation occurred at a higher temperature. Titration of **S4** with the same complementary RNA verified the correct stoichiometry of the melting profiles (Figure 3B; note, the concentration of **S4** was determined according to the Alexa content). Gradual addition of the complementary RNA strand increased the overall absorbance with a constant slope (hypochromic effect due to the hybridization compensates for the increased absorbance), and a turning point of the slope was observed once the amount of the complementary RNA exceeded the fully occupied SNA. The observed turning point at 11.9 equivalents matched well with the correct 12-armed SNA structure.

Radiolabeling. To evaluate the applicability of DOTA as a ⁶⁸Ga-chelating agent on SNAs, **S5** was used as a model in




Figure 3. Melting profile analysis and titration of **S4** with complementary RNA: C AAU GUC UCU CUU UCA UAC UAG. For the formation of free duplex CUA GUA UGA AAG AGA GAC AUU G (2'-O-methyl RNA phosphorothioate) was used.

preliminary radiolabeling experiments. With these small-scale trials (1–2 nmol of **S5**) we also tried to find conditions that minimize precursor loading at the expense of yield. Radiochemical yields of up to 68 MBq were achieved (24% decay corrected yield). Radiochemical purity was measured at up to 69% as measured by PAGE and 73% by ultrafiltration (Figure 4). We observed that size exclusion purification of the reaction




Figure 4. Representative polyacrylamide gel electrophoresis (PAGE) autoradiography image and quantification of radiolabeled SNA $S5[^{68}\text{Ga}]$.

mixture could not sufficiently remove all unbound ^{68}Ga , even when two successive column purifications were used. Also, commonly used solid-phase extraction columns with C8, C18, and hydrophobic lipophilic balance (HLB) solid phases were attempted. Due to the difficulty of separating unbound ^{68}Ga and the low performance of the size exclusion purification, we suspected unspecific binding of ^{68}Ga to the SNA structure. This was confirmed by incubating the end product ($S5[^{68}\text{Ga}]$) in 50 mM ethylenediaminetetraacetic acid/phosphate-buffered saline (EDTA/PBS) at pH 7.4 in 37 °C. As expected, we observed a further 10% increase in the unbound activity fraction after 1 h EDTA challenge, as measured by ultrafiltration. This relatively stable unspecific ^{68}Ga binding to the densely packed ON construct is in agreement with the behavior of the SNAs in MS in which relatively stable multiple sodium adducts were observed (Table 1, entries 1 and 2). Although the small-scale (1–2 nmol of precursor **S5** loading) experiments did not produce acceptable purities, valuable information was obtained, which will aid future in vivo PET/CT imaging studies of SNAs. Due to the unspecific ^{68}Ga binding observed, an indirect labeling method, such as a click reaction with a reactive agent pre-labeled with either ^{68}Ga or ^{18}F , may prove a more suitable choice for SNAs.^{40,41}

CONCLUSION

A two-step procedure that allows controlled assembly of monofunctionalized C_{60} -based SNAs has been described. This preliminary data opens the door for controlled decoration of SNAs with labels or tissue/organ-specific ligands and

possibility integrating them specifically to other delivery vehicles. Despite the multicomponent SPAAC-based assembly and two RP-HPLC purifications, the overall yield of these SNAs proved to be relatively high, ca. 20–30%. We also paid extra attention to the homogeneity of the C_{60} -azide scaffold (**1**). **1** was noticed to be readily contaminated by a hardly distinguishable azide- C_{60} [3 + 2] cycloaddition side product (**2**) that would hamper the assembly, purification, and identification of the SNAs. The homogeneity and authenticity of the SNAs were evaluated by various methods, including RP-HPLC, native PAGE, CE, SEC-MALS, and MS-ESI spectroscopy. While PAGE was a superior technique to evaluate the homogeneity of these C_{60} -based SNAs, SEC-MALS could be used for rough evaluation of the molecular weights. Preliminary radiolabeling experiments suggested that the chelation-based techniques should be replaced by a covalent radiolabeling strategy to prevent unspecific metal ion (^{68}Ga) binding to the densely packed ON shell of these nanoparticles. The described procedure with detailed analytical control of each single step will expectedly promote design of new molecularly defined monofunctionalized SNAs, which may find interesting therapeutic and diagnostic applications.

EXPERIMENTAL SECTION

Synthesis and Purification of the C_{60} -Azide Core (**1**). **1**

was synthesized by Bingel cyclopropanation following the previously published procedure:¹³ Buckminster fullerene C_{60} (0.40 g, 0.56 mmol) was dissolved in dry and degassed (oxygen removed by bubbling with argon) *o*-dichlorobenzene (140 mL). Bis(2-(2-(2-(2-azidoethoxy)ethoxy)ethyl)malonate (2.8 g, 5.6 mmol, 10 equiv), CBr_4 (19 g, 56 mmol, 100 equiv), and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU, 1.7 mL, 11 mmol, 20 equiv) were added, and the mixture was stirred 3 days at room temperature under argon. The mixture was purified by silica gel column chromatography (pore size 60 Å, 230–400 mesh particle size, 40–63 μm particle size, isocratic elution with 2% MeOH in dichloromethane, twice) to yield the desired product **1** (0.66 g, 32%) and a near identically behaving side product **2** (0.65 g, 31%, for further characterization, see Figures S2–S9). A sample (30 mg) of column-purified **1** was further purified by RP-HPLC to yield homogenized **1** (7 mg, 23%, overall yield 15%), which was used for the preparation of SNAs. **1**: ^1H NMR (500 MHz, CDCl_3) δ 4.43 (t, 24H, $J = 4.1$ Hz), 3.75 (t, 24H, $J = 4.1$ Hz), 3.69 (t, 24H, $J = 4.3$ Hz), 3.67 (s, 48H), 3.64 (s, 48H), 3.40 (t, 24H, $J = 4.2$ Hz); ^{13}C NMR (125 MHz, CDCl_3) δ 163.5, 145.8, 141.0, 70.7, 70.0, 69.0, 68.6, 65.8, 50.7, 45.2; MS (ESI-TOF) molecular mass for $\text{C}_{174}\text{H}_{192}\text{N}_{36}\text{O}_{60}\text{Na}_3$ 3816.6, found 3816.4 (calculated from $[(M + 3\text{Na})/3]^{3+}$).

Synthesis of C_{60} -ON Conjugates **C1–C3**, **C5**, and **C7**.

General procedure: BCN-modified oligonucleotide (**ON1–3**, **ON5**, or **ON7**, 0.1 μmol in 60 μL of H_2O) was slowly added to a mixture of C_{60} core **1** (0.5 μmol in 540 μL of DMSO) in a microcentrifuge tube. The reaction mixture was gently shaken overnight at room temperature and subjected to RP-HPLC (Figure 1A and Scheme S2). An analytical RP-HPLC column (250 \times 4.6 mm, 5 μm), a gradient elution from 40% to 100% MeCN in 50 mmol L^{-1} triethylammonium acetate over 30 min, and detection at 260 nm were applied. The C_{60} -ON conjugate (**C1–C7**) and unreacted fullerene core **1** were collected individually and lyophilized to dryness. The authenticity of the products was verified by MS (ESI-TOF) (Figure 1B and Figure S11). Isolated yields (45–50%, only

slight differences in yields between the different conjugates observed) of C1–C7 were determined by UV absorbance at 260 nm.

Synthesis of Alexa-488-Labeled Conjugates C4 and C6. AF488 NHS ester (0.4 μmol in 6 μL of DMSO) was added to a buffered mixture of C₆₀–ON conjugate (50 nmol of C3 or C5 in 60 μL of 0.1 M sodium borate, pH 8.5). The reaction mixture was gently shaken overnight at room temperature and subjected to RP-HPLC. An analytical RP-HPLC column (250 \times 4.6 mm, 5 μm), a gradient elution from 40% to 100% MeCN in 50 mmol L⁻¹ triethylammonium acetate over 30 min, and detection at 260 nm were used. The product fractions were collected and lyophilized to dryness. The authenticity of the products (C4 and C6) was verified by MS (ESI-TOF) (Figure S11). Isolated yields (C4, 32%; C6, 62%) of the products were determined by UV absorbance at 488 nm.

Assembly of SNAs (S1–S6). General procedure: C₆₀–ON conjugate (C1–C7, 20 nmol in 55 μL of H₂O) was mixed with BCN–ON (ON1, ON3, ON5, and ON8–ON10, 240 nmol in 145 μL of H₂O), and 100 μL of 4.65 M NaCl was added. The reaction mixture was gently shaken for 2 days at room temperature, and then one additional equivalent of BCN–ON was added. The mixture was then incubated one more day (72 h total using 1.2 equiv of BCN–ON/azide arm) and subjected to RP-HPLC. An analytical RP-HPLC column Phenomenex, Aeris 3.6 μm WIDEPORX XB-C18 200 Å, 150 \times 4.6 mm, a linear gradient from 5% to 60% MeCN in 50 mmol L⁻¹ triethylammonium acetate over 40 min, a flow rate of 1.0 mL min⁻¹, and detection at 260 nm were used for purification (Figure 1C and Scheme S2). The product (S1–S6) fractions were collected and lyophilized to dryness. Isolated yields (40–57%) of the products were determined by UV absorbance at 260 nm (S1, S2, S5, and S6) and 488 nm (S3 and S4). The obtained SNAs were characterized by MS-ESI (equipped with a hybrid quadrupole orbitrap and nano-ESI ionization) (S1 and S2) and SEC-MALS (S3–S6) (Table 1, Figure 2C, and Figure S12). For the homogeneity and particle size evaluation of S1–S6, see the PAGE (Figure 2B), CE (Figure 2A and Scheme S2), SEC-MALS (Figure 2C, Scheme S2), and DLS experiments described below.

PAGE Analysis of SNAs. Native 6% Tris base, boric acid, EDTA, and acrylamide (TBE) gel were used to check SNAs' purity. A precast gel cover (10 cm \times 10 cm in size, Thermo Fisher Scientific) was fixed into a vertical electrophoresis chamber, and the running buffer (90 mM Tris, 90 mM borate, and 2 mM EDTA, 8.3 pH) was filled into the chamber. SNA samples (5 μL of 0.1 μM SNAs mixed with 5 μL of TBE sample buffer) and a DNA ladder (100, 200–1000 bp; note, the ladder is just used to confirm the quality and comparability of the runs and cannot be used for size evaluation of the SNAs) were loaded and electrophoresed at constant 200 V (45 mA) for approximately 30 min. After completion of electrophoresis, gel was removed from the chamber and the SNA bands were monitored either directly by UV or after staining by SYBR™ Gold Nucleic Acid Stain (Thermo Fisher Scientific).

Capillary Electrophoresis Experiments. Samples were analyzed by capillary zone electrophoresis in a fused silica capillary of 75 μm i.d. and 57 cm effective length. The background electrolyte was 0.3 M citrate buffer, pH 3.1. A voltage of 15 kV and pressure of 0.3 PSI were applied. UV detection at $\lambda = 260$ nm was used.

SEC-MALS Experiments. SEC-MALS was performed using an Agilent Technologies 1260 Infinity II HPLC system (sampler, pump, and UV–vis detector) equipped with a Wyatt Technologies miniDAWN light scattering detector and Wyatt Technologies Optilab refractive index detector. An Agilent AdvanceBio SEC 300 Å 2.7 μm 4.6 \times 300 mm column and 150 mM sodium phosphate, pH 7.0, as mobile phase eluting at a rate of 0.2 mL min⁻¹ and run time of 20 min were used for each experiment. For each run, 4 μL of sample with a SNA concentration of 1 mg mL⁻¹ in Milli-Q water was loaded onto the pre-equilibrated column. Detector signals were aligned with a bovine serum albumin (BSA) standard, which was analyzed prior to SNA samples. The RI and MALS signals were used for the MW calculations using an average refractive index increment (dn/dc) of 0.1703 mL/g.

Melting Experiments (T_m) and Titration of S4 with a Complementary RNA. The melting curves (absorbance vs temperature) were measured at 260 nm on a UV–vis spectrometer equipped with a multiple cell holder and a Peltier temperature controller. The temperature was changed at a rate of 0.5 $^{\circ}\text{C}$ min⁻¹ between 10 and 80 $^{\circ}\text{C}$. The measurements were performed in 10 mmol L⁻¹ sodium cacodylate (pH 7.0) with 0.1 mol L⁻¹ NaCl and 1.0 μmol L⁻¹ ON. T_m values were determined as the maximum of the first derivative of the melting curve. The UV titration of S4 (absorbance vs equivalents of complementary RNA oligonucleotide added) was performed in 10 mmol L⁻¹ sodium cacodylate (pH 7.0) with 0.1 μmol L⁻¹ NaCl and 63 nmol L⁻¹ S4. RNA oligonucleotide with a complementary sequence to S4 was added gradually in the solution, and the total absorbance at 260 nm was monitored with an UV–vis spectrometer. The sequence of complementary RNA was C AAU GUC UCU CUU UCA UAC UAG. For the formation of free duplex, CUA GUA UGA AAG AGA GAC AUU G (2'-O-methyl RNA phosphorothioate) was used.

DLS Experiments. The size of the SNAs was measured at room temperature using a Zetasizer Nano ZS90 (Malvern Instruments Ltd., UK). The settings and conditions for the measurements were as follows: material Protein (RI, 1.450; absorption, 0.001), dispersant water (viscosity, 0.8872 cP; RI, 1.330) temperature was 20 $^{\circ}\text{C}$, and equilibration time was 60 s. Each sample (10 μg of SNA in 100 μL of aqueous 10 mmol L⁻¹ PBS, 2.7 mmol L⁻¹ M KCl, 0.137 mol L⁻¹ NaCl, pH 7.4) was measured three times.

Radiolabeling Experiments. [⁶⁸Ga]GaCl₃ was eluted from an IGG-100 ⁶⁸Ge/⁶⁸Ga generator with 0.1 M HCl through a Strata SCX cartridge into a waste container. The cartridge was then eluted with 300 μL of 1.0 M sodium chloride/0.1 M HCl solution, and an aliquot (200 μL) was transferred to a reaction vial preloaded with a mixture of HEPES (12 mg) and S5 (1–2 nmol) in 50 μL of water. Gentic acid (10 μL , 0.1 M in water) was added as a radical scavenger to counter possible radiolysis. The reaction mixture was then incubated at 70 $^{\circ}\text{C}$ for 15 min. The mixture was cooled on ice after incubation and purified using consecutive Illustra NAP-5 and NAP-10 size-exclusion columns (Cytiva, USA) equilibrated with phosphate-buffered saline (PBS, pH 7.4). This afforded the end product formulation in 1.2 mL of phosphate-buffered saline (PBS). Radiochemical purity was determined by native PAGE and ultrafiltration. PAGE was carried out with TBE-buffered 6% polyacrylamide gels in a Biorad miniprotean II system (Bio-Rad Laboratories, Hercules, CA, USA) ran at 250 V. The gels were developed on BAS-

TR2025 phosphor imaging plates and analyzed with a BAS-5000 scanner (Fuji, Tokyo, Japan). Ultrafiltration was done in triplicate by loading 0.5 mL, 30 kDa Microcon filters (Millipore, Bedford, MA, USA), with 100 μ L of PBS and 1 μ L of reaction mixture. The filters were centrifuged three times for 5 min at 14 000g, with addition of 100 μ L of PBS between spins. The activities of the filter and the filtrate were measured with a 1480 Wizard gamma counter (PerkinElmer/Wallac, Turku, Finland), and the purity was calculated by dividing the filter activity by the total activity.

■ ASSOCIATED CONTENT

SI Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acs.bioconjchem.1c00187>.

Further characterization data of **1** and **2**, monosubstituted C₆₀-conjugates **C1–C7**, and SNAs (**S1–S6**) (PDF)

■ AUTHOR INFORMATION

Corresponding Author

Pasi Virta – Department of Chemistry, University of Turku, FI-20014 Turku, Finland; Department of Biologics, Orion Pharma, 20101 Turku, Finland; orcid.org/0000-0002-6218-2212; Phone: +358 503285719; Email: pamavi@utu.fi

Authors

Vijay Gulumkar – Department of Chemistry, University of Turku, FI-20014 Turku, Finland
Antti Äärelä – Department of Chemistry, University of Turku, FI-20014 Turku, Finland
Olli Moisio – Turku PET Centre, University of Turku, FI-20520 Turku, Finland
Jani Rahkila – Instrument Centre, Faculty of Science and Engineering, Åbo Akademi University, FI-20500 Åbo, Finland
Ville Tähtinen – Department of Chemistry, University of Turku, FI-20014 Turku, Finland
Laura Leimu – Department of Biologics, Orion Pharma, 20101 Turku, Finland
Niko Korsoff – Department of Chemistry, University of Turku, FI-20014 Turku, Finland
Heidi Korhonen – Department of Chemistry, University of Turku, FI-20014 Turku, Finland; orcid.org/0000-0001-6974-9907
Päivi Poijärvi-Virta – Department of Chemistry, University of Turku, FI-20014 Turku, Finland
Satu Mikkola – Department of Chemistry, University of Turku, FI-20014 Turku, Finland
Victor Nesati – Department of Biologics, Orion Pharma, 20101 Turku, Finland
Elina Vuorimaa-Laukkanen – Faculty of Engineering and Natural Sciences, Tampere University, FI-33014 Tampere, Finland
Tapani Viitala – Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, FI-00014 Helsinki, Finland; orcid.org/0000-0001-9074-9450
Marjo Yliperttula – Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, FI-00014 Helsinki, Finland

Anne Roivainen – Turku PET Centre, University of Turku, FI-20520 Turku, Finland

Complete contact information is available at: <https://pubs.acs.org/doi/10.1021/acs.bioconjchem.1c00187>

Author Contributions

[‡]V.G. and A.Ä.: These authors contributed equally.

Author Contributions

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

Financial support from the Academy of Finland (308931) and Business Finland (448/31/2018) is acknowledged.

■ REFERENCES

- (1) Rosi, N. L.; Giljohann, D. A.; Thaxton, C. S.; Lytton-Jean, A.; Han, M. S.; Mirkin, C. A. (2006) Oligonucleotide-Modified Gold Nanoparticles for Intracellular Gene Regulation. *Science* 312, 1027–1030.
- (2) Cutler, J. I.; Auyeung, E.; and Mirkin, C. A. (2012) Spherical Nucleic Acids. *J. Am. Chem. Soc.* 134, 1376–1391. (c) Young, K. L.; Scott, A. W.; Hao, L.; Mirkin, S. E.; Liu, G.; and Mirkin, C. A. (2012) Hollow Spherical Nucleic Acids for Intracellular Gene Regulation Based Upon Biocompatible Silica Shells. *Nano Lett.* 12, 3867–3871.
- (3) Zheng, D.; Giljohann, D. A.; Chen, D. L.; Massich, M. D.; Wang, X. Q.; Iordanov, H.; Mirkin, C. A.; and Paller, A. S. (2012) Topical Delivery of siRNA-based Spherical Nucleic Acid Nanoparticle Conjugates for Gene Regulation. *Proc. Natl. Acad. Sci. U. S. A.* 109, 11975–11980.
- (4) Jensen, S. A.; Day, E. S.; Ko, C. H.; Hurley, L. A.; Luciano, J. P.; Kouri, F. M.; Merkel, T. J.; Luthi, A. J.; Patel, P. C.; Cutler, J. I., et al. (2013) Spherical Nucleic Acid Nanoparticle Conjugates as an RNAi-Based Therapy for Glioblastoma. *Sci. Transl. Med.* 5, 209ra152.
- (5) Alhasan, A. H.; Patel, P. C.; Choi, C. H. J.; and Mirkin, C. A. (2014) Exosome Encased Spherical Nucleic Acid Gold Nanoparticle Conjugates as Potent microRNA Regulation Agents. *Small* 10, 186–192.
- (6) Randeria, P. S.; Seeger, M. A.; Wang, X. O.; Wilson, H.; Shipp, D.; Mirkin, C. A.; and Paller, A. S. (2015) siRNA-based Spherical Nucleic Acids Reverse Impaired Wound Healing in Diabetic Mice by Ganglioside GM3 Synthase Knockdown. *Proc. Natl. Acad. Sci. U. S. A.* 112, 5573–5578.
- (7) Krishnamoorthy, K.; Hoffmann, K.; Kewalramani, S.; Brodin, J. D.; Moreau, L. M.; Mirkin, C. A.; Olvera de la Cruz, M.; and Bedzyk, M. J. (2018) Defining the Structure of a Protein–Spherical Nucleic Acid Conjugate and Its Counterion Cloud. *ACS Cent. Sci.* 4, 378–386.
- (8) Choi, C. H. J.; Hao, L.; Narayan, S. P.; Auyeung, E.; and Mirkin, C. A. (2013) Mechanism for the Endocytosis of Spherical Nucleic Acid Nanoparticle Conjugates. *Proc. Natl. Acad. Sci. U. S. A.* 110, 7625–7630.
- (9) Patel, P. C.; Giljohann, D. A.; Daniel, W. L.; Zheng, D.; Prigodich, A. E.; and Mirkin, C. A. (2010) Scavenger Receptors Mediate Cellular Uptake of Polyvalent Oligonucleotide-Functionalized Gold Nanoparticles. *Bioconjugate Chem.* 21, 2250–2256.
- (10) Narayan, S. P.; Choi, C. H. J.; Hao, L.; Calabrese, C. M.; Auyeung, E.; Zhang, C.; Goor, O. J. G. M.; and Mirkin, C. A. (2015) The Sequence-Specific Cellular Uptake of Spherical Nucleic Acid Nanoparticle Conjugates. *Small* 11, 4173–4182.
- (11) Wu, X. A.; Choi, C. H. J.; Zhang, C.; Hao, L.; and Mirkin, C. A. (2014) Intracellular Fate of Spherical Nucleic Acid Nanoparticle Conjugates. *J. Am. Chem. Soc.* 136, 7726–7733.

- (12) Yamankurt, G., Stawicki, R. J., Posadas, D. M., Nguyen, J. Q., Carthew, R. W., and Mirkin, C. A. (2020) The Effector Mechanism of siRNA Spherical Nucleic Acids. *Proc. Natl. Acad. Sci. U. S. A.* *117*, 1312–1320.
- (13) Li, H., Zhang, B., Lu, X., Tan, X., Jia, F., Xiao, Y., Cheng, Z., Li, Y., Silva, D. O., Schrekker, H. S., Zhang, K., Mirkin, C. A., et al. (2018) Molecular Spherical Nucleic Acids. *Proc. Natl. Acad. Sci. U. S. A.* *115*, 4340–4344.
- (14) Barnaby, S. N., Perelman, G. A., Kohlstedt, K. L., Chinen, A. B., Schatz, G. C., and Mirkin, C. A. (2016) Design Considerations for RNA Spherical Nucleic Acids (SNAs). *Bioconjugate Chem.* *27*, 2124–2131.
- (15) Chinen, A. B., Ferrer, J. R., Merkel, T. J., and Mirkin, C. A. (2016) Relationships between Poly(ethylene glycol) Modifications on RNA-Spherical Nucleic Acid Conjugates and Cellular Uptake and Circulation Time. *Bioconjugate Chem.* *27*, 2715–2721.
- (16) Zhang, K., Hao, H., Hurst, S. J., and Mirkin, C. A. (2012) Antibody-Linked Spherical Nucleic Acids for Cellular Targeting. *J. Am. Chem. Soc.* *134*, 16488–16491.
- (17) Chinen, A. B., Guan, C. M., Ko, C. H., and Mirkin, C. A. (2017) The Impact of Protein Corona Formation on the Macrophage Cellular Uptake and Biodistribution of Spherical Nucleic Acids. *Small* *13*, 1603847.
- (18) Bingel, C. (1993) Cyclopropanierung von Fullerenen. *Chem. Ber.* *126*, 1957–1959.
- (19) Iehl, J., Pereira de Freitas, R., Delavaux-Nicot, B., and Nierengarten, J.-F. (2008) Click chemistry for the Efficient Preparation of Functionalized [60]Fullerene Hexakis-Adducts. *Chem. Commun.*, 2450–2452.
- (20) Grosser, T., Prato, M., Lucchini, V., Hirsch, A., and Wudl, F. (1995) Ring Expansion of the Fullerene Core by Highly Regioselective Formation of Diazafulleroids. *Angew. Chem., Int. Ed. Engl.* *34*, 1343–1345.
- (21) Prato, M., Li, Q. C., Wudl, F., and Lucchini, V. (1993) Addition of Azides to Fullerene C₆₀: Synthesis of Azafulleroids. *J. Am. Chem. Soc.* *115*, 1148–1150.
- (22) Cases, M., Duran, M., Mestres, J., Martin, N., and Solà, M. (2001) Mechanism of the Addition Reaction of Alkyl Azides to [60]Fullerene and the Subsequent N₂ Extrusion to Form Monoimino-[60]fullerenes. *J. Org. Chem.* *66*, 433–442.
- (23) Nierengarten, I., and Nierengarten, J.-F. (2014) Fullerene Sugar Balls: A New Class of Biologically Active Fullerene Derivatives. *Chem. - Asian J.* *9*, 1436–1444.
- (24) Yan, W., Seifermann, S. M., Pierrat, P., and Bräse, S. (2015) Synthesis of Highly Functionalized C₆₀ Fullerene Derivatives and Their Applications in Material and Life Sciences. *Org. Biomol. Chem.* *13*, 25–54.
- (25) Kiviniemi, A., Mäkelä, J., Mäkilä, J., Saanijoki, T., Liljenbäck, H., Poijärvi-Virta, P., Lönnberg, H., Laitala-Leinonen, T., Roivainen, A., and Virta, P. (2012) Solid-Supported NOTA and DOTA Chelators Useful for the Synthesis of 3'-Radiometalated Oligonucleotides. *Bioconjugate Chem.* *23*, 1981–1988.
- (26) Osterlund, T., Aho, A., Äärelä, A., Tähtinen, V., Korhonen, H., and Virta, P. (2020) Immobilized Carbohydrates for Preparation of 3'-Glycoconjugated Oligonucleotides. *Curr. Protoc. Nucleic Acid Chem.*, DOI: 10.1002/cpnc.122.
- (27) Luna Velez, M. V., Verhaegh, G. W., Smit, F., Sedelaar, J. P. M., and Schalken, J. A. (2019) Suppression of Prostate Tumor Cell Survival by Antisense Oligonucleotide-Mediated Inhibition of AR-V7 mRNA Synthesis. *Oncogene* *38*, 3696–3709.
- (28) An, F., Gong, B., Wang, H., Yu, D., Zhao, G., Lin, L., Tang, W., Yu, H., Bao, S., and Xie, Q. (2012) miR-15b and miR-16 Regulate TNF Mediated Hepatocyte Apoptosis via BCL2 in Acute Liver Failure. *Apoptosis* *17*, 702–716.
- (29) Guo, C. J., Pan, Q., Li, D. G., Sun, H., and Liu, B. W. J. (2009) miR-15b and miR-16 are Implicated in Activation of the Rat Hepatic Stellate Cell: An Essential Role for. *J. Hepatol.* *50*, 766–778.
- (30) Mäkilä, J., Jadhav, S., Kiviniemi, A., Käkälä, H., Liljenbäck, H., Poijärvi-Virta, P., Laitala-Leinonen, T., Lönnberg, H., Roivainen, A., and Virta, P. (2014) Synthesis of Multi-Galactose-Conjugated 2'-O-Methyl Oligoribonucleotides and Their in vivo Imaging with Positron Emission Tomography. *Bioorg. Med. Chem.* *22*, 6806–6813.
- (31) Jadhav, S., Käkälä, M., Mäkilä, J., Kiugel, M., Liljenbäck, H., Virta, J., Poijärvi-Virta, P., Laitala-Leinonen, T., Kytö, V., Jalkanen, S., et al. (2016) Synthesis and In Vivo PET Imaging of Hyaluronan Conjugates of Oligonucleotides. *Bioconjugate Chem.* *27*, 391–403.
- (32) Makila, J., Kiviniemi, A., Saanijoki, T., Liljenback, H., Kakela, M., Jadhav, S., Poijarvi-Virta, P., Lonnberg, H., Laitala-Leinonen, T., Virta, P., Roivainen, A., et al. (2019) Noninvasive and Quantitative Monitoring of the Distributions and Kinetics of MicroRNA-Targeting Molecules in Vivo by Positron Emission Tomography. *Mol. Pharmaceutics* *16*, 1507–1515.
- (33) Astakhova, I. K., Santhosh Kumar, T., Campbell, M. A., Ustinov, A. V., Korshun, V. A., and Wengel, J. (2013) Branched DNA Nanostructures Efficiently Stabilised and Monitored by Novel Pyrene-Perylene 2'-Alpha-L-Amino-LNA FRET pairs. *Chem. Commun.* *49*, 511–513.
- (34) Marth, G., Hartley, A. M., Reddington, S. C., Sargisson, L. L., Parcollet, M., Dunn, K. E., Jones, D. D. D., and Stulz, E. (2017) Precision Templated Bottom-Up Multiprotein Nanoassembly Through Defined Click Chemistry Linkage to DNA. *ACS Nano* *11*, 5003–5010.
- (35) Lou, C., Martos-Maldonado, M. C., Madsen, C. S., Thomsen, R. P., Midtgaard, S. R., Christensen, N. J., Kjems, J., Thulstrup, P. W., Wengel, J., and Jensen, K. J. (2016) Peptide-Oligonucleotide Conjugates as Nanoscale Building Blocks for Assembly of an Artificial Three-Helix Protein Mimic. *Nat. Commun.* *7*, 12294.
- (36) https://www.bio-ad.com/webroot/web/pdf/lsr/literature/Bulletin_7277.pdf.
- (37) Cutler, I. J., Zhang, K., Zheng, D., Auyeung, E., Prigodich, E., and Mirkin, C. A. (2011) Polyvalent Nucleic Acid Nanostructures. *J. Am. Chem. Soc.* *133*, 9254–9257.
- (38) Fong, L.-K., Wang, Z., Schatz, G. C., Luijten, E., and Mirkin, C. A. (2018) The Role of Structural Enthalpy in Spherical Nucleic Acid Hybridization. *J. Am. Chem. Soc.* *140*, 6226–6230.
- (39) Randeria, P. S., Jones, M. R., Kohlstedt, K. L., Banga, R. J., Olvera de la Cruz, M., Schatz, G. C., and Mirkin, C. A. (2015) What Controls the Hybridization Thermodynamics of Spherical Nucleic Acids? *J. Am. Chem. Soc.* *137*, 3486–3489.
- (40) Mushtaq, S., Yun, S.-J., and Jeon, J. (2019) Recent Advances in Bioorthogonal Click Chemistry for Efficient Synthesis of Radiotracers and Radiopharmaceuticals. *Molecules* *24*, 3567.
- (41) Keinänen, O., Fung, K., Pourat, J., Jallinoja, V., Vivier, D., Pillarsetty, K. N., Airaksinen, A., Lewis, J. S., Zeglis, B. M., and Sarparanta, M. (2017) Pretargeting of Internalizing Trastuzumab and Cetuximab with a ¹⁸F-Tetrazine Tracer in Xenograft Models. *EJNMMI Res.* *7*, 95.